INVZ
Innoviz Technologies Ltd.
There isn't enough reported data to score INVZ yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
INVZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
INVZ's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
INVZ PE Valuation
INVZ has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
INVZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect INVZ's losses to shrink, with revenue growing.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
INVZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.34 | +$0.23 |
| Q2 2025 | -$0.42 | +$0.25 |
| Q4 2024 | -$0.57 | +$0.27 |
| Q2 2024 | -$0.67 | +$0.32 |
| Q4 2023 | -$0.84 | +$0.10 |
| Q4 2022 | -$0.94 | +$0.60 |
INVZ has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
INVZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.3M | +144% |
| Q4 2025 | $12.7M | +20% |
| Q2 2025 | $27.1M | +98% |
| Q4 2024 | $10.5M | -43% |
| Q2 2024 | $13.7M | +454% |
| Q4 2023 | $18.4M | +649% |
| Q2 2023 | $2.5M | -31% |
| Q4 2022 | $2.5M | -55% |
INVZ has the edge over LCID in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -176% | +254 points |
| Q4 2025 | -165% | +247 points |
| Q3 2025 | -103% | +233 points |
| Q2 2025 | -114% | +2744 points |
| Q4 2024 | -431% | +2462 points |
| Q2 2024 | -412% | +1334 points |
| Q4 2023 | -336% | +2548 points |
| Q2 2023 | -2858% | N/A |
INVZ has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID's revenue has grown year over year for 11 quarters in a row: $350M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
INVZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$52.4M | -$38.4M |
| Q4 2025 | -$10.2M | +$26.5M |
| Q2 2025 | -$28M | +$16.7M |
| Q4 2024 | -$36.7M | +$6.4M |
| Q2 2024 | -$44.7M | +$11.9M |
| Q4 2023 | -$43.1M | +$17.8M |
| Q2 2023 | -$56.6M | -$1.4M |
| Q4 2022 | -$60.8M | +$25.5M |
INVZ has burned cash in almost every quarter: −$105M over the past year, against −$181M the year before.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
INVZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +38.8M shares |
| 1 year | +43% | +71.5M shares |
| 3 years | +84% | +109M shares |
INVZ has 239M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over INVZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
INVZ Net Leverage
INVZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INVZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.0 | Oversold |
| Stochastic | 9.4 | Oversold |
INVZ's weekly RSI is 26 (oversold) and its Stochastic is 9 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
INVZ PE vs Consumer Cyclical Sector
INVZ has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
INVZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.27 | 30% below |
| 20 week MA | $0.38 | 50% below |
| 50 week MA | $0.66 | 71% below |
| 100 week MA | $1.01 | 81% below |
| 200 week MA | $1.49 | 87% below |
INVZ is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
INVZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $15.5 | +56% |
| 2021 | $15.5 | $6.32 | -59% |
| 2022 | $6.32 | $3.72 | -41% |
| 2023 | $3.72 | $2.53 | -32% |
| 2024 | $2.53 | $1.80 | -29% |
| 2025 | $1.80 | $0.95 | -47% |
| 2026 YTD | $0.95 | $0.19 | -80% |
INVZ has finished five years in a row lower, and it's down 80% so far in 2026.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over INVZ on returns for 2026, with the stronger performance.